Patents Assigned to Wyeth
  • Patent number: 9884019
    Abstract: The present invention provides methods of lyophilizing a pharmaceutical substance involving a primary drying step executed at a product temperature at or above the collapse temperature. The invention also provides pharmaceutical substances lyophilized at or above the collapse temperature.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: February 6, 2018
    Assignee: Wyeth LLC
    Inventors: Serguei Tchessalov, Dan Dixon, Nicholas Warne
  • Patent number: 9879024
    Abstract: The present invention provides a new forms of (R)-N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 30, 2018
    Assignees: Progenics Pharmaceuticals., Inc., Wyeth, LLC
    Inventors: Valeriya N. Smolenskaya, Kadum A. Al Shareffi, Julio Perez, Syed M. Shah, Thomas A. Boyd
  • Publication number: 20180016228
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Applicant: WYETH LLC
    Inventors: Justin Keith MORAN, Jianxin GU
  • Patent number: 9856305
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: January 2, 2018
    Assignee: WYETH LLC
    Inventors: John Wozney, Howard Seeherman, Christopher Todd Brown
  • Publication number: 20170333561
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 23, 2017
    Applicant: Wyeth LLC
    Inventors: Amanda R. Alley, William A. Bubnis, Stephanie Shield
  • Patent number: 9822143
    Abstract: This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 21, 2017
    Assignee: Wyeth LLC
    Inventors: Shujun Sun, Christopher Gallo, Brian Kelley
  • Publication number: 20170319518
    Abstract: Sodium ibuprofen compositions and methods of manufacturing tablets and caplets comprising sodium ibuprofen are described. The formulation is advantageous because it allows for the formation of tablets having low sodium content and further provides tablets exhibiting improved physical stability, high tablet hardness and high strength, coupled with excellent dissolution and bioavailability characteristics.
    Type: Application
    Filed: April 20, 2017
    Publication date: November 9, 2017
    Applicant: Wyeth LLC
    Inventors: Jeffery Jon Seyer, Amy Lee Conder, Angela Pearce Taylor, Bonny Rene Shaw
  • Publication number: 20170319711
    Abstract: Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: May 23, 2016
    Publication date: November 9, 2017
    Applicant: WYETH LLC
    Inventors: Hans-Peter Gerber, John Francis DiJoseph, Kiran Manohar Khandke, Kimberly Ann Marquette, Puja Sapra, Lioudmila Gennadievna Tchistiakova
  • Patent number: 9801941
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: October 31, 2017
    Assignee: Wyeth LLC
    Inventors: Amanda Alley, William Bubnis, Stephanie Shield
  • Patent number: 9802890
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: October 31, 2017
    Assignee: WYETH LLC
    Inventors: Justin Keith Moran, Jianxin Gu
  • Publication number: 20170266290
    Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 21, 2017
    Applicant: Wyeth LLC
    Inventors: Mahdi B. FAWZI, Tianmin ZHU, Syed M. SHAH
  • Publication number: 20170258916
    Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 14, 2017
    Applicant: Wyeth LLC
    Inventors: David Hugh Giamalva, Gary Bruce Anderson
  • Patent number: 9757443
    Abstract: The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: September 12, 2017
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Kathrin Ute Jansen, Mark E. Ruppen, Justin Keith Moran, Susan Kay Hoiseth
  • Patent number: 9757444
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: September 12, 2017
    Assignee: Wyeth Holdings LLC
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Publication number: 20170251711
    Abstract: The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is also provided.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 7, 2017
    Applicant: Wyeth LLC
    Inventors: Yong Dai, Alan M. Goldberg, Michael A. Goode, Raymond Alan Bartolucci, James O. Frazier
  • Patent number: 9745354
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: August 29, 2017
    Assignee: Wyeth LLC
    Inventors: Mark E. Ruppen, Justin Keith Moran, Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Narender K. Kalyan, Maninder K. Sidhu, Michael James Flint
  • Patent number: 9738602
    Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 22, 2017
    Assignee: Wyeth LLC
    Inventors: George Anello Chiarello, Ayman Sahli
  • Patent number: 9724343
    Abstract: The present invention provides a compound of formua I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: August 8, 2017
    Assignee: Wyeth, LLC
    Inventors: Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
  • Patent number: 9694078
    Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: July 4, 2017
    Assignee: Wyeth LLC
    Inventors: Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
  • Patent number: RE46518
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: August 22, 2017
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint